Curbing Clots

Rutin, a substance found in apples, could help prevent heart attacks and stroke.

The old adage “An apple a day keeps the doctor away” now has science to back it up: Harvard researchers have found that rutin, a substance contained in that fruit (as well as in onions, buckwheat, and tea), has potent anticlotting powers that could help prevent heart attack and stroke.

Researchers discovered rutin’s antithrombotic property when they screened a set of 5,000 compounds for their ability to block the action of a key protein involved in the formation of vessel-clogging blood clots. When rutin rose to the top of the list, “It was very surprising, and we still don’t understand exactly why it is so potent,” says associate professor of medicine Robert Flaumenhaft, the study’s senior author.

What’s more, rutin could be effective at preventing both the arterial clots that cause heart attacks and strokes and the venous clots that cause deep-vein thrombosis and pulmonary embolism, even though the two types form by somewhat different mechanisms. Existing anticlotting drugs (aspirin, Plavix, Coumadin/warfarin) target one clotting mechanism or the other.

Indeed, if scientists had tried to design a clot-preventing molecule, they could scarcely have created one more perfect than rutin. The protein it blocks—PDI (protein disulfide isomerase)—is essential for protein folding, a critical activity within every cell of the body. Rutin inhibits PDI activity only outside cells, where the protein’s clot-promoting activity takes place.

Health-conscious consumers may be familiar with rutin: it is one of a class of substances called flavonoids (known primarily as antioxidants that may help prevent cancer and slow aging), and is already sold as a nutritional supplement. Because the Food and Drug Administration has already granted it “generally recognized as safe” status, fewer regulatory hurdles apply to the clinical trial Flaumenhaft and his colleagues are beginning to conduct.

Research in humans has not yet compared rutin directly with widely used antithrombotic medications, but one thing is already clear: those medications are not effective enough on their own. People who have one heart attack or stroke are usually prescribed one of them, yet each year there are 400,000 recurrences—a subsequent heart attack or stroke in a patient who’s already had one—in the United States. “Thrombotic disease kills more Americans than cancer, than HIV, than anything else,” says Flaumenhaft. “If you have a drug that improves upon existing options by even 2 or 3 percent, that would still be many thousands of lives saved.”

Read more articles by Elizabeth Gudrais

You might also like

This Astronomer is Sounding a Warning on 'Space Junk'

As debris accumulates in low Earth orbit, the danger of destructive collisions continues to rise.

Isaac Kohlberg to Step Down as Head of Harvard Technology Development

Partnerships and licensing office could become more critical as funding cuts loom

The Professor Who Quantified Democracy

Erica Chenoweth’s data shows how—and when—authoritarians fall.

Most popular

The Latest In Harvard’s Fight with the Trump Administration

Back-and-forth reports on settlement talks, new accusations from the government, and a reshuffling of two federal compliance offices

Hold the Fries

Baked, boiled, and mashed potatoes are better.

The School of Public Health, Facing a Financial Reckoning, Seizes the Chance to Reinvent Itself

Dean Andrea Baccarelli plans for a smaller, more impactful Chan School of 2030.

Explore More From Current Issue

Colorful glass bottles and nautical trinkets line a window shelf, with a ship in a bottle as the centerpiece.

I Spy Creator Walter Wick at the Norman Rockwell Museum 

Illustration of a head in a cloud of oranges

A research study digs into the gut microbiome.

Illustration of Donald Trump and Alan Garber wearing boxing gloves, facing off beneath the quote: “The stakes are so high that we have no choice.”

Introducing a guide to the issues, players, and stakes.